The Diabetic Retinopathy Clinical Research Network qualified 660 patients with DME and randomly assigned them to treatment with anti-VEGF agents such as aflibercept, bevacizumab, or ranibizumab. This evidence concerns the gene VEGFA and diabetic retinopathy.